HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 21, No 03, March 2017 – Get to Know TCM       » Chinese Scientists in Rice Breakthrough       » Leading Regional Medical Technology Trade Associations Reinforce their Commitment to Evidence-based Healthcare       » New Study Finds Extensive Use of Fluorinated Chemicals in Fast Food Wrap       » What Doesn't Kill You Makes You Stronger       » Life Under Pressure       » Understanding the Genetics of Human Height      
EYE ON CHINA
Neovia Enrolls First Patient in Cancer Trial for Immunotherapy Enhancing Drug
BEIJING – Neovia Oncology (Beijing, Taiwan, & Seattle), has begun its first Phase 1 clinical trial for its lead cancer drug NEV-801, a novel, multi-inhibitor drug able to enhance immunotherapy response in patients with advanced drug-resistant cancers.

During its pre-clinical proof-of-concept studies, conducted in China and America, NEV-801 showed exciting potential, including curative effects, to treat Chronic Myeloid Leukaemia that had become resistant to the gold-standard therapy (imatinib), as well as advanced colon cancer that had become resistant to multiple therapies.

No bone-marrow toxicity or gastro-intestinal side effects were observed at the highest administered doses in pre-clinical studies.

The initial clinical trial will be run by principal investigators in America at Dana Farber Cancer Institute, Boston; and Sarah Cannon Research Institute, Nashville. Neovia also plans studies in China in the near future.

Immunotherapy rarely controls clinically significant tumours that fail to express target antigens, and thereby fail to elicit an effective immune response. However, there is mounting evidence that tumour antigen production can be precisely stimulated to promote immune recognition and response.

NEV-801 is a conjugated compound made from an alkaloid isolated from the Chinese tree Camptotheca acuminate and podophyllotoxin derived from the roots of the may apple plant that grows in the wild in North America. Combined, it becomes a simultaneous multi-inhibitor of Topoisomerase I and Topoisomerase II activity, HIF-1 transcriptional activation, and hypoxic induction of VEGF mRNA and protein expression, targeting Werner syndrome protein (WRN) (a RecQ helicase), thereby overcoming MDR gene 1-mediated resistance. The simultaneous inhibition of multiple cancer pathways forces distressed tumours to express target antigens, thereby potentially enhancing the efficacy of immunotherapy.

"Patient enrolment marks the formal beginning of a clinical trial and so we are excited to get underway after much preparation and hard work by our team," said Gerald Su, COO, "This is the first program to have advanced through Neovia's innovative development pipeline that includes more than 60 potential drugs. It represents a milestone in the transition of Neovia to clinical-stage and validates us to potential investors and partners who can now help us grow and provide more potential therapies to cancer patients."

Neovia Oncology is developing safe, multi-inhibitor cancer drugs that enhance immune response to overcome drug resistance and seeks partners and investors for growth. ( www.neoviaoncology.com )

Source: Neovia Oncology Ltd

Click here for the complete issue.

NEWS CRUNCH  
news Philip Morris International and British American Tobacco receive award from PETA science group for AOP developments
news 6th Asia-Pacific Breast Cancer Summit to take place in Hong Kong
news MIT Hacking Medicine Robotics in Singapore!
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Healthcare Focus: LUNGS
February:
War on CANCER
March:
Get to Know TCM
April:
Diabetics Technology
May:
The Piece of Your Mind - Brain Health/Science
June:
Women & Men's Health
July:
Food Science & Technology
August:
Eye Care/ Eye Health
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2017 World Scientific Publishing Co Pte Ltd  •  Privacy Policy